All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

MANIFEST study: Should CPI-0610 be used as an add-on to ruxolitinib in patients with advanced MF?

Jan 20, 2020
Share:

The MPN Hub were pleased to speak to John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US, during the 61st American Society of Hematology Meeting & Exposition in Orlando, US. Based on the MANIFEST study, we asked: Should the bromodomain and extraterminal domain inhibitor (BETi), CPI-0610, be used as an add-on to ruxolitinib for symptom control in patients with advanced myelofibrosis (MF)?

John Mascarenhas discusses the MANIFEST study of the BETi, CPI-0610, in patients with myelofibrosis. He discusses the study enrollment criteria, primary endpoints, the treatment regimen and the overall patient outcomes. He also describes the preclinical data and the rationale for the study.

MANIFEST study: Should CPI-0610 be used as an add-on to ruxolitinib in patients with advanced MF?